Affiliation: Yale University
- Glycine treatment of the risk syndrome for psychosis: Report of two pilot studiesScott W Woods
Yale University School of Medicine, New Haven, CT, USA Connecticut Mental Health Center, 34 Park Street, New Haven, CT, USA Electronic address
Eur Neuropsychopharmacol 23:931-40. 2013..Further studies of agents that facilitate NMDA receptor function in risk syndrome patients are supported by these preliminary findings. ..
- Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998-2005 and 2008-2011Scott W Woods
Department of Psychiatry, Yale University, New Haven, CT, United States Electronic address
Schizophr Res 148:99-104. 2013..Antipsychotic medication use rates have generally been rising among youth with psychiatric disorders, but little is known about use rates of antipsychotics or other psychotropic medications in patients at high risk for psychosis...
- Efficient allocation of patients to treatment cells in clinical trials with more than two treatment conditionsS W Woods
Connecticut Mental Health Center, Yale University School of Medicine Department of Psychiatry, New Haven 06508, USA
Am J Psychiatry 155:1446-8. 1998..The authors propose that it may be more efficient to allocate unequal proportions of the total sample size to treatments when more than two treatments are being compared...
- Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot studyScott W Woods
Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
Br J Psychiatry Suppl 51:s96-101. 2007..Research studies for the treatment of the putative prodromal phase of psychotic disorders have begun to appear...
- Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled studyScott W Woods
Department of Psychiatry, Yale University, Connecticut Mental Health Center, New Haven 06519, USA
J Clin Psychiatry 69:546-54. 2008..The goal of this study was to evaluate the efficacy and safety of levetiracetam versus placebo for tardive dyskinesia (TD)...
- Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal StudyScott W Woods
PRIME Prodromal Research Clinic, Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
Schizophr Bull 35:894-908. 2009..The strong evidence of diagnostic validity for the prodromal risk syndrome for first psychosis raises the question of its evaluation for inclusion in Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition)...
- Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyScott W Woods
Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
J Clin Psychiatry 71:463-74. 2010..The current study aimed to compare the incidence of tardive dyskinesia with atypical vs conventional antipsychotics using methods similar to those from a previous prospective cohort study at our site in the 1980s...
- Best practices: racial and ethnic effects on antipsychotic prescribing practices in a community mental health centerScott W Woods
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06515, USA
Psychiatr Serv 54:177-9. 2003
- Effects of development on olanzapine-associated adverse eventsScott W Woods
Department of Psychiatry, Yale University, New Haven, CT, USA
J Am Acad Child Adolesc Psychiatry 41:1439-46. 2002..Atypical antipsychotic medications are increasingly prescribed for child and adolescent patients. Relatively little information on adverse events (AEs), specifically in children or adolescents taking atypical antipsychotics, is available...
- The economic burden of bipolar diseaseS W Woods
Department of Psychiatry, Connecticut Mental Health Center, Yale University School of Medicine, New Haven 06519, USA
J Clin Psychiatry 61:38-41. 2000..Despite the burden imposed by bipolar illness and the availability of several effective treatments for the illness, many bipolar patients in the United States continue to face significant barriers to care...
- Chlorpromazine equivalent doses for the newer atypical antipsychoticsScott W Woods
Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
J Clin Psychiatry 64:663-7. 2003..Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed...
- The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndromeScott W Woods
Connecticut Mental Health Center, CT, USA
Schizophr Res 123:199-207. 2010..It will be important to demonstrate through well-designed field trials whether the diagnostic criteria can be used with reliability in everyday clinical practice...
- Characteristics of participants and nonparticipants in medication trials for treatment of schizophreniaS W Woods
Connecticut Mental Health Center, New Haven 06519, USA
Psychiatr Serv 51:79-84. 2000....
- Estimated yield of early detection of prodromal or first episode patients by screening first degree relatives of schizophrenic patientsS W Woods
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
Schizophr Res 52:21-7. 2001..The yield of new cases obtained by screening relatives of current patients appears to be low if the purpose is to recruit a sample for an early intervention study over a relatively short period of time...
- Does the manic/mixed episode distinction in bipolar disorder patients run true over time?S W Woods
Department of Psychiatry, Treatment Research Program, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park St, New Haven, CT 06519, USA
Am J Psychiatry 158:1324-6. 2001..The authors sought to determine whether the manic/mixed episode distinction in patients with bipolar disorder runs true over time...
- Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosisLarry J Seidman
Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Arch Gen Psychiatry 67:578-88. 2010..Early detection and prospective evaluation of clinical high-risk (CHR) individuals who may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset and for testing preventive interventions...
- Control group bias in randomized atypical antipsychotic medication trials for schizophreniaScott W Woods
Treatment Research Program, Department of Psychiatry and Biostatistics Division, Yale University School of Medicine, New Haven, Conn 06519, USA
Arch Gen Psychiatry 62:961-70. 2005..This strategy requires an assumption of constancy, that the novel medication will perform the same way in a study with only active controls as it would have in a placebo-controlled trial...
- Prospective observations of emerging psychosisJoanna Lifshey Rosen
Prevention through Risk Identification, Management, and Education PRIME Clinic, Department of Psychiatry, Yale University School of Medicine, Yale Psychiatric Research at Congress Place, 301 Cedar Street, New Haven, Connecticut 06519, USA
J Nerv Ment Dis 190:133-41. 2002..Discussion focuses on the dimensional quality of the transition both from the prodrome to psychosis and from psychosis to recovery...
- Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapyCindy J Aaronson
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
J Clin Psychiatry 69:418-24. 2008..We provided open CBT treatment to patients who subsequently participated in a maintenance treatment study. This article reports on predictors and trajectory of response in 381 participants who completed treatment at 4 sites...
- Public-academic partnerships: early intervention for psychotic disorders in a community mental health centerVinod H Srihari
Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT 06519, USA
Psychiatr Serv 60:1426-8. 2009..The authors describe the critical contribution of such partnerships in evaluating the cost-effectiveness of early intervention in a "real-world" U.S. setting...
- Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisThomas H McGlashan
Department of Psychiatry, Yale University School of Medicine, 301 Cedar St, New Haven, CT 06519, USA
Am J Psychiatry 163:790-9. 2006..This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia...
- Comorbid diagnoses in patients meeting criteria for the schizophrenia prodromeJoanna L Rosen
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06520 8098, USA
Schizophr Res 85:124-31. 2006..These findings lay the groundwork for further examination of the role that comorbid conditions play in the development, course, and severity of schizophrenia...
- Recruitment and treatment practices for help-seeking "prodromal" patientsThomas H McGlashan
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Schizophr Bull 33:715-26. 2007..References for details are noted...
- Best practices: surveillance and management of diabetes in a CMHC populationVinod H Srihari
Connecticut Mental Health Center, 34 Park St, 2nd Floor, New Haven, CT 06519, USA
Psychiatr Serv 58:1151-3. 2007....
- Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal populationRalph E Hoffman
Yale New Haven Psychiatric Hospital, 184 Liberty Street LV108, New Haven, CT 06519, USA
Br J Psychiatry 191:355-6. 2007..no drug) and length of speech illusion, with the latter strongly predicting subsequent conversion during medication-free intervals but not during olanzapine treatment...
- Cognitive behavior therapy for early psychosis: a comprehensive review of individual vs. group treatment studiesJohn R Saksa
Yale University School of Medicine, New Haven, Connecticut, USA
Int J Group Psychother 59:357-83. 2009....
- Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment StudyKeith A Hawkins
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
Schizophr Res 105:1-9. 2008..We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome...
- The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatmentLynelle E Thomas
PRIME Research Clinic, New Haven, CT, USA
Child Adolesc Psychiatr Clin N Am 15:109-33. 2006..Some centers are beginning to examine if and how currently used prodromal diagnostic strategies and intervention studies might inform recognition and treatment of younger patients possibly prodromal for childhood-onset schizophrenia...
- Effects of ethnicity on psychotropic medications adherenceEsperanza Diaz
Yale University School of Medicine, 34 Park Street, Office 273 A, New Haven, CT 06519, USA
Community Ment Health J 41:521-37. 2005..Further studies are needed to better understand and improve adherence among Hispanics and African-Americans...
- Treatment histories of patients with a syndrome putatively prodromal to schizophreniaAdrian Preda
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Psychiatr Serv 53:342-4. 2002..These data suggest that patients who present with a syndrome putatively prodromal to schizophrenia constitute a clinical population. Research into treatment interventions is indicated...
- Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validityTandy J Miller
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06520, USA
Am J Psychiatry 159:863-5. 2002....
- Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysisC Bruce Baker
Yale University School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, New Haven 06519, USA
Depress Anxiety 17:1-9. 2003..Study designs better tailored to address the relevant clinical question would test these hypotheses more appropriately than previous studies...
- Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study designC Bruce Baker
Yale University School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, Treatment Research Program, New Haven 06519, USA
Depress Anxiety 17:10-8. 2003..This re-analysis is performed in a companion article [Baker et al. 2003, Depress Anxiety 17:1-9]...
- Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodromeScott W Woods
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Biol Psychiatry 54:453-64. 2003..The prodromal phase of schizophrenic disorders has been described prospectively. The present study aimed to determine the short-term efficacy and safety of olanzapine treatment of prodromal symptoms compared with placebo...
- Quantitative analysis of sponsorship bias in economic studies of antidepressantsC Bruce Baker
Department of Psychiatry, Yale School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut 06519, USA
Br J Psychiatry 183:498-506. 2003..Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited...
- Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locusJoel Gelernter
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
Am J Psychiatry 161:59-66. 2004..Genetic linkage analysis can provide the means to identify genomic locations harboring susceptibility loci for genetically influenced disorders. Identifying loci for social phobia was the goal of this study...
- Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliabilityTandy J Miller
Yale University, New Haven, CT, USA
Schizophr Bull 29:703-15. 2003..It also presents data suggesting that excellent interrater reliability can be established for diagnosis in a day-and-a-half-long training workshop...
- Adherence to conventional and atypical antipsychotics after hospital dischargeEsperanza Diaz
Department of Psychiatry and the Treatment Research Program, Yale University, 34 Park Street, Room 273A, New Haven, CT 06519, USA
J Clin Psychiatry 65:354-60. 2004..We examined the interaction of several predictors such as gender, severity of illness, attitudes toward medications, side effects, and dose frequency...
- Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medicationJohn R Saksa
Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
Gen Hosp Psychiatry 26:233-6. 2004..When adjunctive antipsychotic medications are discontinued, bipolar patients' clinical symptoms can remain unchanged. Others are, however, at risk for manic relapse...
- Rater bias in a blinded randomized placebo-controlled psychiatry trialSue M Marcus
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
Stat Med 25:2762-70. 2006..Despite the uncertainty involved in assessing bias that may be unobserved and unconscious, we will show how to derive a bound for the impact of rater bias...
- The effect of pharmacotherapist characteristics on treatment outcome in panic disorderJack M Gorman
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
Depress Anxiety 17:88-93. 2003..Depression and Anxiety 17:88-93, 2003...
- Mediators and moderators in early intervention researchNicholas J K Breitborde
Department of Psychiatry, University of Arizona, Tucson, Arizona 85724 5002, USA
Early Interv Psychiatry 4:143-52. 2010..Particular attention will be devoted to discussing the ways in which the identification of mediator and moderator variables may help to advance the field of early intervention in psychiatry...
- Prevention of schizophrenia: can it be achieved?Cheng Lee
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06579, USA
CNS Drugs 19:193-206. 2005..Drug and psychosocial intervention is indicated as part of tertiary prevention to prevent further disability in the illness...
- Multifamily psychoeducation for first-episode psychosis: a cost-effectiveness analysisNicholas J K Breitborde
Department of Psychiatry, University of Arizona, Tucson, AZ 85724 5002, USA
Psychiatr Serv 60:1477-83. 2009..Thus the goal of this study was to investigate the cost of providing a specific psychoeducation program-multifamily group psychoeducation-to individuals with first-episode psychosis and their families...
- North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia researchJean Addington
Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
Schizophr Bull 33:665-72. 2007....
- Social functioning in individuals at clinical high risk for psychosisJean Addington
Department of Psychiatry, University of Toronto, Toronto, Canada
Schizophr Res 99:119-24. 2008....
- Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorderJonathan D Huppert
Center for Treatment and Study of Anxiety, University of Pennsylvania School of Medicine, 6th Floor, 3535 Market St, Philadelphia, PA 19104, USA
Am J Psychiatry 161:1485-7. 2004..Placebo effects in treatment of three anxiety disorders were compared...
- Assessment of social judgments and complex mental states in the early phases of psychosisShannon M Couture
University of North Carolina at Chapel Hill, Department of Psychology, CB 3270, Davie Hall, Chapel Hill, NC 27599 3270, USA
Schizophr Res 100:237-41. 2008..Social cognition plays an important role in the functioning of individuals with psychosis. In this study, we explored two areas of social cognition not previously investigated early in the course of psychosis...
- Independent evaluator knowledge of treatment in a multicenter comparative treatment study of panic disorderDavid Roll
Clinical Psychology Doctoral Program, Long Island University CW Post Campus, Brookville, NY 11548, USA
Neuropsychopharmacology 29:612-8. 2004..Implications of these findings on interpretation of the treatment study are discussed, and recommendations are made for improving blindness procedures...
- Cost-efficacy of individual and combined treatments for panic disorderR Kathryn McHugh
Department of Psychology, Center for Anxiety and Related Disorders, Boston University, Boston, MA 02215, USA
J Clin Psychiatry 68:1038-44. 2007..As psychosocial, pharmacologic, and combined treatments have all demonstrated efficacy in the treatment of panic disorder, cost-efficacy analysis provides an additional source of information to guide clinical decision making...
- Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North AmericaTyrone D Cannon
Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Los Angeles, CA 90095
Arch Gen Psychiatry 65:28-37. 2008....
- Facial affect recognition in individuals at clinical high risk for psychosisJean Addington
Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
Br J Psychiatry 192:67-8. 2008..Deficits in facial affect recognition appear to be present before the onset of psychosis and may be a vulnerability marker...
- Treatment of psychosis at onsetTandy J Miller
Am J Psychiatry 159:153. 2002
- Genome scan for loci predisposing to anxiety disorders using a novel multivariate approach: strong evidence for a chromosome 4 risk locusBelhassen Kaabi
Laboratory of Epidemiology and Ecology of Parasites, Institut Pasteur de Tunis, Tunis, Tunisia
Am J Hum Genet 78:543-53. 2006..This method could be applied to other complex traits for which shared genetic-liability factors are thought to be important, such as substance dependencies...
- Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorderThomas V Hicks
Department of Psychology, University of Vermont, Burlington, VT, USA
J Consult Clin Psychol 73:506-14. 2005....
- Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorderStefan G Hofmann
Department of Psychology, Boston University, Boston, MA 02215, USA
J Consult Clin Psychol 75:374-9. 2007..Multilevel moderated mediation analyses provided preliminary support for the notion that changes in panic-related cognitions mediate changes in panic severity only in treatments that include CBT...
- Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorderSusan D Raffa
Research Phobia Clinic at Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY, USA
J Nerv Ment Dis 196:548-55. 2008..Other possible reasons for differential relapse rates and treatment implications are discussed...
- Enhancing the Prospective Prediction of PsychosisScott Woods; Fiscal Year: 2007..Each site has provefi its ability to recruit prodromal patients in a previous collaboration. ..
- TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTICScott Woods; Fiscal Year: 2004..The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work. ..
- TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIESScott Woods; Fiscal Year: 2003..Thus, we are proposing to add these aims. ..
- MULTI-CTR COMPARATIVE TREATMENT STUDY OF PANIC DISORDERScott Woods; Fiscal Year: 1993..An additional goal will be to examine the implication of prior psychoactive substance abuse for treatment outcome as well as the utilization of substances as coping mechanisms for anxiety and panic...
- TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIESScott Woods; Fiscal Year: 1999..Nonresponders will be randomized to a study comparing paroxetine with continued CBT. In addition to the main questions, possible predictors of response and relapse will be examined as well as possible mediators of response. ..